HPL Group History

  • License agreement with F.Hoffmann-La Roche Ltd.

  • Installation, Qualification & Validation

  • Process validation, stability studies

  • Commercial production started

  • Agreement signed with NOVARTIS for contract manufacturing

  • Launch cephalosporin products from dedicated facility

  • Launch cream & ointment products from separate facility

  • HPL Established state-of-the-art facility for Small Volume Parenterals, Ophthalmic, Lyophilized & Bio-generic products

  • Metered Dose Inhaler (MDI) facility establishment

  • Marketing & Distribution agreement with MSD Pharmaceuticals Private Limited (a subsidiary of Merck & Co. Inc., USA)

  • Anti-cancer products launch from HPL dedicated oncology facility

  • Distribution agreement signed with ELI LILLY

  • Sergel became number one pharmaceutical brand in Bangladesh

  • Started dedicated sterile cephalosporin facility

  • Launched hormone products from HPL dedicated facility

  • Launched HPL's first product in USA